For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 10,292,620 | |||
| General and administrative | 12,202,692 | |||
| Total operating expenses | 22,495,312 | |||
| Loss from operations | -22,495,312 | |||
| Change in estimated fair value of warrant liability | 0 | |||
| Gain on settlement of warrants | 0 | |||
| Loss on issuance of related party convertible notes payable at fair value | 0 | |||
| Change in estimated fair value of related party convertible notes payable | 0 | |||
| Interest expense | 20,250 | |||
| Interest income | 287,710 | |||
| Total other income (expense), net | 267,460 | |||
| Net loss | -22,227,852 | |||
| Basic EPS | -1.06 | |||
| Diluted EPS | -1.06 | |||
| Basic Average Shares | 21,021,817 | |||
| Diluted Average Shares | 21,021,817 | |||
ACTUATE THERAPEUTICS, INC. (ACTU)
ACTUATE THERAPEUTICS, INC. (ACTU)